GLYCAM1
Putative glycosylation-dependent cell adhesion molecule 1
Also known as: GLCM1_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for GLYCAM1 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
47 residues, UniProt reviewed canonical sequence.
>Q8IVK1|GLYCAM1
1 MKFFMVLLPA SLASTSLAIL DVESGLLPQL SVLLSNRLRG KTCQTGPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GLYCAM1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.58
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 0% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Cellular components
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GLYCAM1 as an antibody target. Whether an autoantibody or antibody against GLYCAM1 could matter depends on whether native GLYCAM1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GLYCAM1 is annotated at the cell surface, where native GLYCAM1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label GLYCAM1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...